Viz.ai and Novartis Partner to Accelerate Cancer Care Through AI

Viz.ai, a leader in AI-backed imaging and care coordination, has announced a strategic collaboration with pharmaceutical company Novartis to develop proprietary AI-powered workflows within the Viz Oncology Suite. The partnership represents a significant expansion of Viz.ai's capabilities into oncology, targeting critical gaps in cancer care delivery.

The collaboration will focus on improving the identification and stratification of patients diagnosed with prostate and breast cancers based on crucial risk factors. By leveraging Viz.ai's care coordination platform, which features more than 50 FDA-cleared algorithms for analyzing medical imaging data, the companies aim to accelerate access to guideline-based precision treatments while addressing persistent delays in diagnosis and treatment.

Two new AI-powered offerings will emerge from this partnership. Viz Prostate Cancer will identify eligible patients for guideline-based treatment and facilitate referrals to appropriate specialists. Viz Breast Cancer will support breast oncologists by automating patient reviews, aggregating risk-relevant data, introducing therapeutic guidelines, and promoting coordination among multidisciplinary care teams.

"We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer," said Dr. Chris Mansi, CEO and cofounder of Viz.ai. "This collaboration is part of our broader strategic expansion into oncology, furthering Viz.ai's mission to fundamentally transform healthcare through intelligent care coordination."

This partnership builds on Viz.ai's growing portfolio of pharmaceutical collaborations. In May, the company partnered with Regeneron and Sanofi to deploy and study an AI-enabled workflow tool for COPD management. The Viz COPD Module utilizes AI and electronic health record data to identify and manage high-risk COPD patients. Additionally, in 2023, Viz.ai signed a multi-year agreement with Bristol Myers Squibb to release Viz HCM, an AI-enabled algorithm that reviews routine electrocardiograms to identify suspected cases of hypertrophic cardiomyopathy.

For Novartis, this collaboration represents continued investment in digital health solutions for chronic disease management. The company previously partnered with Dawn Health in 2023 to develop remote monitoring and management tools for conditions including multiple sclerosis, hypertension, cardiovascular disease, and breast cancer. In 2022, Novartis also collaborated with Anumana to develop AI tools for detecting cardiovascular diseases through ECG analysis.

The Viz.ai-Novartis partnership underscores the growing convergence of AI technology and pharmaceutical expertise in addressing healthcare delivery challenges, particularly in oncology where timely intervention can significantly impact patient outcomes.

Click here for the original news story.